Related coverage linked through entity extraction aliases.
Jun 30, 2026
Epcoritamab plus lenalidomide cut progression risk by 60% in R/R DLBCL in a phase 3 trial. Five-year AUGMENT follow-up supports R2 in indolent NHL; a phase 2 penpulimab-lenalidomide-R-GemOx trial showed activity in DLBCL.
Jul 11, 2026
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
Apr 27, 2026
A Phase 1b/2 trial in 28 patients found nivolumab plus modified FOLFIRINOX was well tolerated before surgery in borderline-resectable pancreatic cancer. Seventy-nine percent proceeded to surgery, with complete tumor removal in all resected patients.
Mar 04, 2026
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
Feb 15, 2026
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Feb 14, 2026
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
